Firms focused on future development and commercialization of facial aesthetics pipeline.

Genzyme will develop future hyaluronic acid (HA) dermal filler products according to a commercialization agreement with Mentor.


The first product launch under the agreement is scheduled to occur internationally in early 2007, with a worldwide launch of an additional product in late 2007.


Genzyme and Mentor will join resources to develop a longer-lasting HA dermal filler. With Genzyme’s history in HA development and manufacturing, Mentor has created a partnership that will allow its facial aesthetics pipeline to expand significantly. All the products will be introduced into Mentor’s current distribution network, maximizing the revenue opportunity.

Previous articleAMRI Launches Drug Discovery Database
Next articleEmisphere’s Orally Dosed Insulin Shown to Be Effective and Safe